Abstract
Aim: The aim of this study was to analyze the epidemiological and survival characteristics of 1770
ovarian cancer patients diagnosed and treated in Ege University Hospital between 1992 and 2017 and
to compare the results with the literature.
Materials and Methods: Data recorded to CANREG-4 program in EUH between 1992-2017 by EU
Fight Against Cancer Research and Application Center (EUKAM) were grouped according to WHO
and SEER systems. For statistical analysis, Chi-square method and general linear modeling and
Kaplan-Meier analysis were performed. In Kaplan-Meier analysis, Log Rank (Mantel-Cox), Breslow
(Generalized Wilcxon) and Tarone-Ware methods were used. p<0.05 was accepted as significant.
Results: Ovarian cancer is the third most common gynecologic malignancy with a total of 1770 cases
(21.3%). It was mostly seen at the ages between 50-59 (30.1%). The most common histologic subtype
was serous carcinoma (32.3%).
The disease is mostly diagnosed in the metastatic stage (63.6%). Overall survival rates of 5 and 10
years were 56.4% and 40.0%, respectively. Median survival was 76 months. The 5-year and 10-year
survival rates in gynecologic cancers were 70% and 47.2%, respectively; this rate was 56.4% and
40% in ovarian cancer cases, respectively. Prognosis and survival were found to be worse than
endometrial and cervical cancer.
Conclusion: Ovarian cancer has an important place among gynecologic cancers due to high mortality
rates. When 25 years data of our hospital was evaluated, demographic and histopathologic data were
found similar with the literature, additionally survival was found similar in metastatic disease according
to developed countries.
References
- Siegel, R., et al., Cancer statistics, 2014. CA: a cancer journal for clinicians, 2014. 64 (1): 9-29.
- Ferlay, J., et al., GLOBOCAN 2012 v1. 0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International agency for research on cancer, 2013. 2016.
- Şencan, İ. and B. Keskinkılıç, Türkiye kanser istatistikleri. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu, 2017.
- http://seer.cancer.gov/statfacts/html/ovary.html (Accessed on April 24.
- Weiderpass, E. and J.E. Tyczynski, Epidemiology of patients with ovarian cancer with and without a BRCA1/2 mutation. Molecular diagnosis & therapy, 2015. 19 (6): 351-64.
- Sopik, V., et al., Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. Gynecologic oncology, 2015. 138 (3): 757-61.
- Robboy, S.J., Robboy's pathology of the female reproductive tract. 2009: Elsevier Health Sciences.
- La Vecchia, C., Ovarian cancer: epidemiology and risk factors. European journal of cancer prevention, 2017. 26 (1): 55-62.
- Webb, P.M. and S.J. Jordan, Epidemiology of epithelial ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 2017. 41: 3-14.
- Permuth-Wey, J. and T.A. Sellers, Epidemiology of ovarian cancer, in Cancer epidemiology. 2009, Springer. p. 413-437.
- Michels, K.A., et al., Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA oncology, 2018. 4 (4):516-21.
- Whittmore, A.S., et al., Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies: II. Invasive epithelial ovarian cancers in white women. American journal of epidemiology, 1992. 136 (10):1184-203.
- Chowdhury, R., et al., Breastfeeding and maternal health outcomes: a systematic review and meta‐analysis. Acta paediatrica, 2015. 104: 96-113.
- Sieh, W., et al., Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International journal of epidemiology, 2013. 42 (2): 579-89.
- Terplan, M., E.J. Smith, and S.M. Temkin, Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. Cancer Causes & Control, 2009. 20 (7): 1139-50.
- SANTIN, A., et al., SECRETION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OVARIAN CANCER. European journal of gynaecological oncology, 1999. 20 (3): 177-81.
- Merogi, A., et al., Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Human pathology, 1997. 28 (3): 321-31.
- Heintz AP, O.F., Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U., Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:145-60.
Abstract
Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası tanı alan ve tedavisi yapılan 1770 over
kanserli olgunun epidemiyolojik ve sağ kalım özelliklerini analiz etmek ve sonuçlarını literatürle
karşılaştırmaktır.
Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından
toplanan over kanseri verileri CANREG özel bilgisayar programına kaydedilmiş, DSÖ ve SEER
sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistiksel analizlerde Ki-kare, General Linear
Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier sağ kalım analizinde Log Rank
(Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik
analizlerde p<0,05 istatistiksel olarak anlamlı kabul edilmiştir.
Bulgular: Over kanseri toplam 1770 olgu sayısıyla (%21,3) en sık görülen üçüncü jinekolojik
malignitedir. Over kanserli olguların en sık görüldüğü yaş grubu 50-59 yaştır (%30,1). En sık histolojik
alt tipi seröz karsinomdur (%32,3). Hastalık en sık metastatik evrede tanı almaktadır (%63,6). Beş ve
10 yılık genel sağ kalım oranı sırasıyla %56,4 ve %40,0 olarak saptanmıştır. Medyan sağ kalım süresi
76 ay olarak hesaplanmıştır. Jinekolojik kanserlerde beş ve 10 yıllık sağ kalım oranları sırasıyla %70
ve %47,2 iken; bu oran over kanseri olgularında sırasıyla %56,4 ve %40 olarak saptanmıştır. Prognoz
ve sağ kalımın, endometrium ve serviks kanser olgularına göre daha kötü olduğu görülmüştür.
Sonuç: Over kanseri, jinekolojik kanserler arasında önemli bir yer tutmaktadır. Hastanemizin 25 yıllık
kayıtları değerlendirildiğinde, demografik verilerin ve histopatolojik bulguların literatür ile uyumlu
olduğu, sağ kalım sürelerinin ise gelişmiş ülkeler ile benzer olduğu görülmektedir
References
- Siegel, R., et al., Cancer statistics, 2014. CA: a cancer journal for clinicians, 2014. 64 (1): 9-29.
- Ferlay, J., et al., GLOBOCAN 2012 v1. 0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International agency for research on cancer, 2013. 2016.
- Şencan, İ. and B. Keskinkılıç, Türkiye kanser istatistikleri. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu, 2017.
- http://seer.cancer.gov/statfacts/html/ovary.html (Accessed on April 24.
- Weiderpass, E. and J.E. Tyczynski, Epidemiology of patients with ovarian cancer with and without a BRCA1/2 mutation. Molecular diagnosis & therapy, 2015. 19 (6): 351-64.
- Sopik, V., et al., Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. Gynecologic oncology, 2015. 138 (3): 757-61.
- Robboy, S.J., Robboy's pathology of the female reproductive tract. 2009: Elsevier Health Sciences.
- La Vecchia, C., Ovarian cancer: epidemiology and risk factors. European journal of cancer prevention, 2017. 26 (1): 55-62.
- Webb, P.M. and S.J. Jordan, Epidemiology of epithelial ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 2017. 41: 3-14.
- Permuth-Wey, J. and T.A. Sellers, Epidemiology of ovarian cancer, in Cancer epidemiology. 2009, Springer. p. 413-437.
- Michels, K.A., et al., Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA oncology, 2018. 4 (4):516-21.
- Whittmore, A.S., et al., Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies: II. Invasive epithelial ovarian cancers in white women. American journal of epidemiology, 1992. 136 (10):1184-203.
- Chowdhury, R., et al., Breastfeeding and maternal health outcomes: a systematic review and meta‐analysis. Acta paediatrica, 2015. 104: 96-113.
- Sieh, W., et al., Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International journal of epidemiology, 2013. 42 (2): 579-89.
- Terplan, M., E.J. Smith, and S.M. Temkin, Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. Cancer Causes & Control, 2009. 20 (7): 1139-50.
- SANTIN, A., et al., SECRETION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OVARIAN CANCER. European journal of gynaecological oncology, 1999. 20 (3): 177-81.
- Merogi, A., et al., Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Human pathology, 1997. 28 (3): 321-31.
- Heintz AP, O.F., Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U., Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:145-60.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Supplement |
| Authors | |
| Publication Date | December 31, 2019 |
| Submission Date | February 15, 2019 |
| Published in Issue | Year 2019 |